Flamel Technologies, Inc

Latest News

April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 4, 2008
Flamel Technologies Fourth Quarter and Year End 2007 Earnings Results Conference Call,
8:30 EST

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet

Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Also available:
"Novel sustained release formulation of IFN-alfa-2b-XL, improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial" click here

"Novel Sustained Release Formulation of IL-2 Improves Pharmacokinetics Performance
and Demonstrates Potent Activation of Immunological Cell Line" click here

Micropump® Technologies

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info

November 1, 2006
Flamel Technologies Announces Third Quarter Results

October 23, 2006
Flamel Technologies Welcomes FDA Approval of COREG CR™

October 20, 2006
FDA Approves New, Once-a-Day COREG CR(TM) for the Treatment of Three Key Cardiovascular Conditions

July 31, 2006
Flamel Technologies Announces Second Quarter Results
Conference Call: Tuesday August, 1st, at 8:30 AM EDT
US: 800-374-1498
Int'l: +1-706-634-7261
ID: 3668963
Webcast

June 12, 2006
Flamel Technologies Announces Results of Annual Meeting

May 19, 2006
Flamel Technologies Announces Receipt of Milestone from GlaxoSmithKline

May 4, 2006
Flamel Technologies Announces that RHEI Pharmaceuticals has Licensed Flamel's ASACARD® (Controlled-Release Aspirin) for China and Taiwan

May 3, 2006
Flamel Technologies Announces First Quarter Results
Conference Call: Thursday May, 4th, at 8:30 AM EDT
US: 800-374-1498
Int'l: +1-706-634-7261
ID: 8474990

April 24, 2006
Flamel Technologies Announces Projected Release Date of First Quarter Results
and Conference Call
Conference Call: Thursday May, 4th, at 8:30 AM EDT
US: 800-374-1498
Int'l: +1-706-634-7261
ID: 8474990

March 7, 2006
Flamel Technologies Announces Fourth Quarter and Year-End Results
Conference Call Webcast
Conference Call Replay
Until March 22
US: 800-642-1687
Int'l: +1-706-645-9291
ID: 6135376

March 2, 2006
Flamel Technologies Announces Projected Release Date of Fourth Quarter and Annual Results, Conference Call

January 11, 2006
Flamel Technologies Announces Appointment of Lodewijk J.R. de Vink to its Board of Directors